PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Tumor development often suppresses the patient's natural antitumor immune response.
• Immune checkpoint inhibitors are a novel class of drugs designed to reverse this suppression.
• Programmed death 1 (PD-1) is a key immune checkpoint receptor targeted by these inhibitors.

Purpose of the Study:

• To provide pharmacists with an understanding of PD-1's role in immune modulation and cancer treatment.
• To review the clinical efficacy and safety data of PD-1 inhibitors.
• To discuss pharmacokinetic, pharmacodynamic, and cost considerations of PD-1 inhibitors.

Main Methods:

• Review of clinical trial data for PD-1 inhibitors (nivolumab and pembrolizumab).
• Analysis of objective response rates and survival data in advanced melanoma and non-small cell lung cancer (NSCLC).
• Examination of immune-mediated adverse events and their management strategies.

Main Results:

• Nivolumab and pembrolizumab are approved for advanced melanoma and metastatic NSCLC, with objective response rates of 25-40% and durable responses.
• Phase III trials show improved survival with nivolumab compared to chemotherapy in advanced melanoma and NSCLC.
• PD-1 inhibitors demonstrate improved survival over ipilimumab in advanced melanoma.
• Immune-mediated adverse events occur in ≤16% of patients and are generally manageable.

Conclusions:

• PD-1 inhibitors represent a significant advancement in cancer immunotherapy, offering improved survival and durable responses.
• Effective management strategies exist for immune-mediated adverse events, allowing for continued treatment.
• Understanding the role of PD-1 and the characteristics of these agents is crucial for pharmacists in cancer care.